Loading
Old version — revision 1
This is a fixed snapshot of XPRIZE Healthspan, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/xprize-healthspan.md — the filesystem corpus, unchanged. Not an edit.
A $101 million incentive competition launched in 2023 that rewards a therapy restoring at least a decade of muscle, cognitive and immune function in older adults.
XPRIZE Healthspan is a seven-year, $101 million incentive competition launched in November 2023 that offers its grand prize to a team demonstrating a therapy that restores at least a decade of function in three domains — muscle, cognition and immunity — in adults aged 50 to 80, using a treatment course of no more than a year. Its significance to the field lies less in the money than in the endpoint: it is the most detailed public attempt to define what a successful Healthspan intervention would have to show.
Incentive prizes are used where a goal is well defined, a solution is plausible, and no market pays for the intermediate steps. The XPRIZE Foundation, which ran the Ansari prize for suborbital spaceflight and later competitions in genomics and carbon removal, applies the model by specifying an outcome and letting teams choose the route.
The Healthspan competition's design responds to a specific problem. No regulator recognizes aging as an indication, so no company can run a registrational trial against it, and the field has no qualified surrogate endpoint that would let a shorter trial substitute for decades of follow-up. The prize sidesteps both by scoring measured function rather than mortality or biomarkers: if a 70-year-old performs across three domains as a 60-year-old would, the intervention has restored ten years of function by the competition's definition, whatever it did to any clock.
The competition was announced with a $101 million purse funded principally by the Hevolution Foundation, a Saudi-backed nonprofit that has become one of the largest funders of aging biology, and by Chip Wilson, the founder of Lululemon, who has facioscapulohumeral muscular dystrophy and funds research on it. The published competition guidelines specify the population, the treatment window and the scoring of each domain.1
The prize is tiered by effect size. The largest award goes to a team restoring twenty years of function; smaller awards go to fifteen and ten years. Milestone payments are made to semifinalist teams during the competition to fund the work, which addresses the standard criticism of prizes — that they reward only the winner and therefore attract only the already-funded.
The judging design constrains what can win. Treatment must be delivered within a defined window of up to one year, so a lifelong regimen does not qualify. Function must improve in all three domains, which excludes single-tissue interventions: a drug that rebuilds muscle without touching cognition or immunity scores zero on two thirds of the assessment. Participants are drawn from a general older population rather than from a disease cohort.
The competition's most useful output may be its measurement framework rather than its winner.
Muscle. Skeletal muscle mass, strength and power decline steeply with age, and the resulting sarcopenia predicts falls, hospitalization and mortality. Grip strength, gait speed and chair-rise time are validated, cheap, and correlate strongly with outcomes; gait speed alone predicts survival in older adults across large pooled cohorts,2 which makes muscle the least contentious domain. It is also the domain where exercise produces large effects, setting a demanding comparator for any drug, and where Myostatin inhibition has repeatedly added mass without adding proportionate strength. Training adjuncts can subtract as well as add: repeated cold-water immersion immediately after resistance training reduces the muscle gains that training produces, among the better-replicated findings on heat and cold exposure.
Cognition. Age-related cognitive change is heterogeneous and slow, and the available instruments have practice effects that complicate repeated testing over a year. Distinguishing a genuine restoration of processing speed or executive function from familiarity with the test is a real methodological problem, and the competition's handling of it is watched closely.
Immunity. Immune aging encompasses thymic involution, narrowing of the naive T-cell repertoire, accumulation of senescent lymphocytes, and the chronic sterile inflammation that accompanies them. Vaccine response is the standard functional readout. This is the domain with the weakest consensus on what to measure, and the one where a positive result would be most informative.
Requiring all three at once is the design's sharpest feature. It operationalizes the Geroscience hypothesis directly: if aging is a shared upstream driver of chronic disease, as the field's founding statement of the position argues,3 an intervention on that driver should move multiple systems together. An entrant that improves one domain has demonstrated a useful drug; an entrant that improves all three has demonstrated something about aging.
What a win would and would not proveRestoring measured function in three domains over one year would be the strongest human evidence any geroprotective intervention has produced. It would not show that lifespan is extended, that mortality falls, or that the effect persists after treatment stops. Function and survival are correlated but not the same, and the competition's timeframe cannot address the second.
Registered teams span a wide range of approaches: repurposed drugs including Rapamycin and metformin analogues, Senolytics, plasma-derived and blood-factor therapies, cell and stem-cell treatments, reprogramming approaches, NAD-raising compounds, hormonal interventions, and structured training and nutrition protocols. Several entrants are academic groups; several are companies for whom the prize functions as non-dilutive funding and validation.
The breadth is itself informative. A competition scored on function rather than mechanism attracts entrants with no shared theory of aging, which means the results will be a comparative test of approaches that have never been run against a common endpoint.
Three objections have been raised.
The first concerns feasibility. No intervention has ever been shown to restore a decade of function in any of the three domains in humans, let alone all three, within a year. Skeptics argue the target is set so far beyond current capability that the prize will go unclaimed and the tiered lower awards will do the real work.
The second concerns measurement. Composite functional scores can be gamed, and a team that optimizes training and testing conditions may produce apparent gains without underlying biological change. Practice effects in cognitive testing and learning effects in physical assessments are well documented, and the competition's protocols have to control for both.
The third concerns funding provenance. Hevolution's association with the Saudi state has drawn objections from researchers who decline funding on those grounds, and the competition's dependence on it is a governance question the foundation has addressed only briefly.
The prize's contribution to the field is likely to be the trial infrastructure and the endpoint definitions rather than a winning therapy. If several teams run year-long, function-scored interventions in older adults under a common protocol, the resulting data would be the closest thing the field has produced to a head-to-head comparison, and it would give regulators something concrete to evaluate when the question of aging as an indication next arises — the same question Nir Barzilai's TAME trial was designed to force.
The unresolved issue is what happens if nothing works. A well-designed, well-funded competition producing no qualifying entrant across seven years would be a substantial negative result, and one the field has so far had little practice interpreting. Its advocates would attribute the failure to the difficulty of the target; its critics would read it as evidence that the near-term optimism surrounding geroscience has not been earned.
statementXPRIZE Foundation. "XPRIZE Healthspan: Competition Guidelines." XPRIZE Foundation, 2023.↩The organiser's own rulebook: it establishes what the competition asks for, and is not evidence about any entrant or result.
paperStudenski, S. et al. "Gait Speed and Survival in Older Adults." JAMA, 2011.↩A pooled analysis of observational cohorts, so gait speed predicts survival without any evidence that raising it raises survival.
paperKennedy, B.K., Berger, S.L., Brunet, A. et al. "Geroscience: Linking Aging to Chronic Disease." Cell, 2014. ↩